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Photodynamic Therapy (PDT) is a clinical procedure
that is showing promising results in the treatment of
certain types of cancer, including melanomas, oesopha-
geal and retinal cancers [1-4]. The search for molecules
suitable for use in PDT is a field of continuing interest.
These molecules need to possess certain characteristics,
including high affinity for tumour tissues and intense
absorption in a region where biological tissues are rela-
tively transparent. Porphyrin derivatives have become
prime targets as sensitizers with potential to become
good PDT agents, and have already been in use for over
a decade in clinical PDT (ex: Foscan®). We report the
synthesis and characterization of a meso-tetra-(3-
hydroxy)-phenyl-porphyrin (T(OH)PP) derivative to
which a naphthyl isocyanate group was attached, giving
the meso-tetra-(phenoxy-3-carbonyl-1-amino-naphthyl)-
porphyrin (T(NAF)PP (Figure 1).
The synthesized compound showed considerably
enhanced photostability compared with the parent T
(OH)PP (photodegradation quantum yield 4.65 × 10
-4).
The photosensitizer triplet state is normally considered
to be essential for PDT, and to lead to the formation of
cytotoxic oxygen species [5,6]. The lifetimes and quan-
tum yields of the triplet state of T(NAF)PP were evalu-
ated and presented typical values for this type of
compounds. The quenching rate constant by molecular
oxygen and singlet oxygen yield were also determined.
The photodynamic effect in human carcinoma HT-29
cells was evaluated, and this novel porphyrin showed
good properties as a sensitizer in photodynamic therapy
with an in vitro cytotoxicity IC50 value of 6.80 μgm L
-1
for 24 h incubation.
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